Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems. They ...

Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) turned in stellar performances in 2018. Abbott's shares jumped 27%, while DexCom stock more than doubled. It's a different story so far this ...

ORLANDO -- In a three-way head-to-head comparison of continuous glucose monitors (CGMs), all performed well in an outpatient setting in type 1 diabetes patients, researchers reported here. Comparing ...

DexCom is a major player in the continuous glucose monitoring (CGM) market. These devices help diabetes patients monitor their blood sugar levels in real time throughout the day, an activity that is ...

Abbott Laboratories and Dexcom are the biggest players in the market for continuous glucose monitoring devices. Abbott has a vast lineup of products beyond that and an overall diversified healthcare ...